Denmark's Leo Pharma has agreed to buy US medical dermatology company Timber Pharmaceuticals in a move that will expand its pipeline of therapies for rare skin diseases.
Sarepta Therapeutics has decided not to continue the development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy (DMD) therapy Exondys 51.
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.